Investor Presentation

Ref: MHL/Sec&Legal/2026-27/42 August 27, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation of the Investors & Analyst Meet scheduled to be held today, i.e., August 27, 2026 at 04:00 p.m. (IST). A copy of the said presentation is also being uploaded on the Company’s website at www.metropolisindia.com You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head – Legal & Secretarial Encl: a/a Investor & Analyst Meet 2026 Strengthen the core. Expand adjacencies. Compound shareholder value. Diagnostics trusted by Doctors and Patients alike Metropolis Healthcare Limited SAFE HARBOUR Safe Harbour This presentation has been prepared by Metropolis Healthcare Limited for information purposes only. It does not constitute a prospectus, offering circular or offering memorandum, and is not a recommendation regarding any securities of the Company. It may contain forward-looking statements based on the beliefs, opinions and expectations of the Company as on the date of this presentation. These do not guarantee future performance and involve risks and uncertainties that are difficult to predict, including changes in economic, business, competitive, technological and regulatory conditions. The Company undertakes no obligation to publicly revise any forward-looking statement, except as required under applicable law. This presentation contains three-year directional ambitions expressed as ratios and revenue mix. They assume mid-teen volume-led revenue growth, no scheduled price increase, convergence of acquired businesses to company-level margins, delivery of the laboratory transformation and automation programme, continued improvement in centre productivity, and no material adverse change in the regulatory, competitive, tariff or reimbursement environment. Actual outcomes may differ materially. METROPOLIS AT A GLANCE A strong national network and legacy built over 45 years 209 / 5,000 750 ₹1,646 Cr Laboratories and Towns in India, plus FY26 revenue across B2C collection centres five international markets and B2B 30,000 prescribing specialists, and every leading hospital chain is a client. By Region B2C is 57% of revenue, through own and franchisee networks. West 50% South 27% B2B keeps the labs full: hospitals, labs and corporates send steady volume. North 18% East 5% Clinician trust and quality are the moat Revenue mix by geography, % · map not to scale MARKET CONTEXT Majority market is unorganised - and three shifts broadening it The shift to organised players is real, but gradual. 37% $11  28.5 Bn 60% Indian diagnostics market to 2034, Of mortality from non-communicable at 11% CAGR 15% disease Unorganised / standalone Organised chains Hospital-based labs 01 · SHIFT TO ORGANISED CARE 02 · HEALTHCARE BEYOND METROS 03 · ADVANCING TREATMENT PATHWAYS ● Expectations on accuracy, ● New hospital capacity and Tier ● Targeted therapies and biologics consistency and service are rising 2/3 access ● Molecular, genomic and ● Share moves to quality-led ● More high-end testing outsourced immunological testing expand providers SCIENTIFIC CAPABILITY  THE COMPETITIVE MOAT Specialty is not an automatic win “Instruments are easy to add. The confidence of WHAT CANNOT BE REPLICATED specialists is earned over time.” QUICKLY Interpretation takes years to build, and it is what clinicians buy. 35 NABL labs and 2 CAP accredited genomics labs Medical Advisory Board of 60 experts 2,200 347  36 99% / 99.99% First listed Indian diagnostics company with a GoI patent, in TB Tests - Oncology, Added in FY26 and EQAS score / monitoring neurology, nephrology, Q1 FY27 report accuracy allergy Growth goes to specialty depth and clinician trust PERFORMANCE · FY2426 Three years of broad-based, profitable growth Group basis, ₹ Crore. REVENUE FROM OPERATIONS EBITDA PROFIT AFTER TAX ₹ Crore ₹ Crore ₹ Crore 1,646 401 191 1,331 325 1,190 285 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 17.6% CAGR · FY26 23.6% 18.6% CAGR · FY26 23% 22.2% CAGR · FY26 19% ● Margin reached 24.4% while absorbing a loss-making acquisition - organic margin was 25.9%, up 140 bps. ● Volume-led - patient volume grew 12% and test volume 13%, with no price increase. LEADERSHIP Promoter led, professionally driven A leadership team built for the next level of growth. Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Founder & Non – Executive Promoter & Executive Managing Director Non - Independent Director Chairperson Sameer Patel Avadhut Joshi Diya Suri Dr. Kirti Kazi Chief Financial Officer Chief Business Chief People Officer Chief Scientific & Development Officer Innovation Officer Bhoopendra Rajawat Kannan Alangadan Mohan Menon Pinakin Shah Chief Business Officer Chief Business Officer Chief Marketing Officer Chief Information Officer West and East South Glen Menezes Umesh Rai Ravikumar Kartha Dr. Monika Prabhakar Group Head – Customer Head - Emerging Business Group Head - Internal Group Head - Lab Operations Success Assurance and Business Excellence ENABLER · PEOPLE AND TALENT Talent is the enabler across Leadership, a training pipeline and a deep clinical bench. LEADERSHIP AND SCALE DOCTORS AND SCIENTIFIC TALENT Leadership strengthened at CXO and CXO1 The bench behind the specialty menu Over 6,000 professionals, 44% of them 30,000 prescribing specialists women Revenue per employee up 15% in FY26 Medical Advisory Board of 60+ experts MiLES UGC-certified medical technology Genetic counsellors, molecular pathologists courses and bioinformaticians A culture built on science, compassion and integrity. GOVERNANCE · BOARD AND SHAREHOLDING Board, governance framework and shareholding Board composition, governance framework and the shareholding structure. 10 5 48.9% 46.2% Directors on the Board Independent directors, Promoter and promoter Institutional holding, FII one a woman group holding plus DII GOVERNANCE FRAMEWORK SHAREHOLDING AND CAPITAL RETURN ● Promoter led, professionally driven ● No private equity overhang: 5% Warburg Pincus exited in ● Five Board committees per the 10% 2015, Carlyle exited fully in Listing Regulations July 2020 ● Bonus issue of 31, record 36% date 20 March 2026, 15.55 crore shares allotted ● FY26 dividend about 22% Promoter DII FPI Retail and other of profit after tax Metropolis, Our Scientific Capabilities and growth STRATEGY Metropolis – Way forward OUR STRATEGIC IDENTITY A technology-led and scientifically differentiated company, consistently delivering profitable growth and sustained value creation for stakeholders. 01 02 03 04 05 Lead with Differentiate Compound Deliver the Strong Technology Scientifically Profitable Growth Brand Promise Governance Pioneer AI and Scientific excellence Scale the core Empower consumers, Promoter led and automation across and uncompromising profitably and clinicians and professionally driven, the lab, the network quality, setting the expand adjacencies employees through underpinning the four and the customer industry benchmark. with disciplined precise, pillars above. journey. capital allocation. compassionate care. EBITDA expansion to 27 99.99% report accuracy Company-wide automation 2,200+ specialty tests 28% 5,000+ touchpoints, 750 Fully Compliant ISO 27001 / 27701 · DPDP 99% EQAS · Improve ROCE towns STRATEGY Growth engines Capital goes to five growth engines, supported by two enablers. 01 02 03 04 05 Network TruHealth Specialty Technology Inorganic Scaling to 1,000 Wellness, Advanced testing Digital platforms, Selective, aligned stores, adding new radiology and to 45% of revenue, automation and AI assets via a proven adjacencies. consults together. from 40% in to lift productivity. playbook. Q1FY27 Science [Showing first 8,000 characters — download PDF for full document]